Épisodes

  • Can oral semaglutide reduce heart failure events in patients with heart failure with preserved ejection fraction?

    Can oral semaglutide reduce heart failure events in patients with heart failure with preserved ejection fraction?
    Mar 5 2026
    Oral semaglutide reduced heart failure hospitalizations and cardiovascular death in type 2 diabetes patients with existing heart failure, particularly those with preserved ejection fraction, but showed no benefit in those without baseline heart failure. Modern total hip replacements demonstrate excellent longevity, with over 92% of implants surviving revision-free at 30 years. A pharmacist-led opioid and benzodiazepine tapering program in older adults showed no significant advantage over usual care.
    Afficher plus Afficher moins
    5 min
  • 2025 San Antonio Breast Cancer Symposium: Key Updates in Early-Stage HER2+ Breast Cancer

    2025 San Antonio Breast Cancer Symposium: Key Updates in Early-Stage HER2+ Breast Cancer
    Mar 3 2026
    Drs. Isaacs and Traina discuss new data in HER2+ breast cancer from the 2025 San Antonio Breast Cancer Symposium, focusing on early-stage studies including DESTINY-Breast11 and DESTINY-Breast05 and how data from these studies could potentially impact patient care in the future.
    Afficher plus Afficher moins
    14 min
  • CLL at ASH 2025: BRUIN Studies and a Triplet for Richter Transformation

    CLL at ASH 2025: BRUIN Studies and a Triplet for Richter Transformation
    Mar 2 2026
    Drs. Wierda and O’Brien discuss emerging data showing the non-covalent BTK inhibitor pirtobrutinib outperforming traditional chemoimmunotherapy and showing favorable efficacy and safety versus ibrutinib in CLL. They also highlight promising early results from a triplet regimen for Richter transformation, suggesting the best survival outcomes yet seen in this historically high‑risk, hard‑to-treat population.
    Afficher plus Afficher moins
    Indisponible
  • Could new pulmonary embolism guidelines safely reduce hospitalizations for some patients?

    Could new pulmonary embolism guidelines safely reduce hospitalizations for some patients?
    Feb 27 2026
    New AHA/ACC guidelines overhaul pulmonary embolism management with a five-tier risk classification, endorsing ED discharge for low-risk patients and DOACs as first-line therapy. A JAMA trial confirms IV acetaminophen adds modest but real pain relief when combined with morphine. A large cohort study shows SGLT2 inhibitors dramatically reduce kidney, cardiovascular, and liver complications in diabetic cirrhosis patients.
    Afficher plus Afficher moins
    5 min
  • Evolving HER2+ Testing and Targeted Therapies in GI Cancers: Latest Insights From ESMO 2025

    Evolving HER2+ Testing and Targeted Therapies in GI Cancers: Latest Insights From ESMO 2025
    Feb 26 2026
    Drs. Cytryn, Foote, and Thummalapalli discuss recent data on HER2 testing modalities and the prevalence of HER2 positivity across hepatobiliary, upper GI, and colorectal cancers, highlighting implications for precision medicine. The conversation reviews the latest clinical trial findings and the evolving landscape of HER2-targeted therapies, with insights into optimal treatment sequencing for various GI cancer subtypes.
    Afficher plus Afficher moins
    17 min
  • OnabotulinumtoxinA and Migraine: Clinical Insights and Recent Evidence

    OnabotulinumtoxinA and Migraine: Clinical Insights and Recent Evidence
    Feb 24 2026
    Drs. Ailani and Dougherty discuss onabotulinumtoxinA, a cornerstone treatment for chronic migraine, which reduces headache days and disability when given regularly with the PREEMPT protocol. They emphasize its unique benefits and how it pairs with CGRP therapies, oral preventives, and lifestyle changes for individualized care.
    Afficher plus Afficher moins
    8 min
  • Can achieving prediabetes remission cut CV death and heart failure risk?

    Can achieving prediabetes remission cut CV death and heart failure risk?
    Feb 19 2026
    Three major studies reshape preventive care. Long-term follow-up from diabetes prevention trials, published in The Lancet Diabetes & Endocrinology, shows that achieving remission of prediabetes—normalizing glucose levels—cuts cardiovascular death or heart failure risk by about 50%, with benefits lasting decades. In The Lancet, a multicohort analysis of 540,000 adults found obesity increases risk of severe infection by 70%, with nearly threefold higher infection-related hospitalization or death in severe obesity. Finally, a randomized trial in The Lancet Child & Adolescent Health found no increased risk of eczema or respiratory illness in infants receiving acetaminophen versus ibuprofen, providing reassurance about its safety.
    Afficher plus Afficher moins
    5 min
  • HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

    HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025
    Feb 18 2026
    Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological cancers, showing promising results even in patients with low HER2 expression. They shared impressive clinical trial successes while emphasizing the importance of ongoing research into treatment sequencing and patient safety.
    Afficher plus Afficher moins
    13 min